Cargando…

PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil

Immune checkpoint blockade (ICB) agents are prominent immunotherapies for the treatment of advanced melanoma. However, they fail to promote any durable clinical benefit in a large cohort of patients. This study assessed clinical and molecular predictors of ICB response and survival in advanced melan...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorroche, Bruna Pereira, Teixeira, Renan de Jesus, Pereira, Caio Augusto Dantas, Santana, Iara Viana Vidigal, Vujanovic, Lazar, Vazquez, Vinicius de Lima, Arantes, Lidia Maria Rebolho Batista
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047789/
https://www.ncbi.nlm.nih.gov/pubmed/36980349
http://dx.doi.org/10.3390/diagnostics13061041
_version_ 1785014015362072576
author Sorroche, Bruna Pereira
Teixeira, Renan de Jesus
Pereira, Caio Augusto Dantas
Santana, Iara Viana Vidigal
Vujanovic, Lazar
Vazquez, Vinicius de Lima
Arantes, Lidia Maria Rebolho Batista
author_facet Sorroche, Bruna Pereira
Teixeira, Renan de Jesus
Pereira, Caio Augusto Dantas
Santana, Iara Viana Vidigal
Vujanovic, Lazar
Vazquez, Vinicius de Lima
Arantes, Lidia Maria Rebolho Batista
author_sort Sorroche, Bruna Pereira
collection PubMed
description Immune checkpoint blockade (ICB) agents are prominent immunotherapies for the treatment of advanced melanoma. However, they fail to promote any durable clinical benefit in a large cohort of patients. This study assessed clinical and molecular predictors of ICB response and survival in advanced melanoma. A retrospective analysis was performed on 210 patients treated with PD-1 or CTLA-4 inhibitors at Barretos Cancer Hospital, Brazil. PD-L1 expression was assessed by immunohistochemistry using formalin-fixed paraffin-embedded tumor tissues collected prior to ICB therapy. Patients were divided into responders (complete and partial response and stable disease for more than 6 months) and non-responders (stable disease for less than 6 months and progressive disease). Among them, about 82% underwent anti-PD-1 immunotherapy, and 60.5% progressed after the ICB treatment. Patients that received ICB as first-line therapy showed higher response rates than previously treated patients. Higher response rates were further associated with superficial spreading melanomas and positive PD-L1 expression (>1%). Likewise, PD-L1 positive expression and BRAF V600 mutations were associated with a higher overall survival after ICB therapy. Since ICBs are expensive therapies, evaluation of PD-L1 tumor expression in melanoma patients should be routinely assessed to select patients that are most likely to respond.
format Online
Article
Text
id pubmed-10047789
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100477892023-03-29 PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil Sorroche, Bruna Pereira Teixeira, Renan de Jesus Pereira, Caio Augusto Dantas Santana, Iara Viana Vidigal Vujanovic, Lazar Vazquez, Vinicius de Lima Arantes, Lidia Maria Rebolho Batista Diagnostics (Basel) Article Immune checkpoint blockade (ICB) agents are prominent immunotherapies for the treatment of advanced melanoma. However, they fail to promote any durable clinical benefit in a large cohort of patients. This study assessed clinical and molecular predictors of ICB response and survival in advanced melanoma. A retrospective analysis was performed on 210 patients treated with PD-1 or CTLA-4 inhibitors at Barretos Cancer Hospital, Brazil. PD-L1 expression was assessed by immunohistochemistry using formalin-fixed paraffin-embedded tumor tissues collected prior to ICB therapy. Patients were divided into responders (complete and partial response and stable disease for more than 6 months) and non-responders (stable disease for less than 6 months and progressive disease). Among them, about 82% underwent anti-PD-1 immunotherapy, and 60.5% progressed after the ICB treatment. Patients that received ICB as first-line therapy showed higher response rates than previously treated patients. Higher response rates were further associated with superficial spreading melanomas and positive PD-L1 expression (>1%). Likewise, PD-L1 positive expression and BRAF V600 mutations were associated with a higher overall survival after ICB therapy. Since ICBs are expensive therapies, evaluation of PD-L1 tumor expression in melanoma patients should be routinely assessed to select patients that are most likely to respond. MDPI 2023-03-09 /pmc/articles/PMC10047789/ /pubmed/36980349 http://dx.doi.org/10.3390/diagnostics13061041 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sorroche, Bruna Pereira
Teixeira, Renan de Jesus
Pereira, Caio Augusto Dantas
Santana, Iara Viana Vidigal
Vujanovic, Lazar
Vazquez, Vinicius de Lima
Arantes, Lidia Maria Rebolho Batista
PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
title PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
title_full PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
title_fullStr PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
title_full_unstemmed PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
title_short PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
title_sort pd-l1 tumor expression as a predictive biomarker of immune checkpoint inhibitors’ response and survival in advanced melanoma patients in brazil
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047789/
https://www.ncbi.nlm.nih.gov/pubmed/36980349
http://dx.doi.org/10.3390/diagnostics13061041
work_keys_str_mv AT sorrochebrunapereira pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil
AT teixeirarenandejesus pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil
AT pereiracaioaugustodantas pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil
AT santanaiaravianavidigal pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil
AT vujanoviclazar pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil
AT vazquezviniciusdelima pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil
AT aranteslidiamariarebolhobatista pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil